#Ireland #Galway #Cigna Healthcare #Neurent Medical #NEUROMARK

Neurent Medical's Expanded Treatment Access for Chronic Rhinitis

Neurent Medical, renowned for its innovative non-surgical approaches to chronic rhinitis, has taken a significant step forward for patients. Effective September 15, 2025, Cigna Healthcare will recognize the NEUROMARK treatment by removing CPT 31242 posterior nasal nerve ablation from its list of experimental procedures. This policy shift is poised to greatly improve patient access to essential treatments for managing chronic rhinitis, lifting previous constraints that impeded ENT physicians in delivering care to Cigna patients.

Importance of the CPT 31242 Reclassification

The reclassification signifies a growing acknowledgment by payers of the therapeutic merit behind posterior nasal nerve ablation procedures. According to Brian Shields, CEO of Neurent Medical, this moment is pivotal for both ENT providers and patients. The acknowledgment of CPT 31242 as a valid diagnostic code underscores the evolving understanding of chronic rhinitis and the effective role targeted, minimally invasive interventions like NEUROMARK play in treating the condition.

NEUROMARK Technology Overview

The NEUROMARK System employs impedance-controlled, low-power radiofrequency (RF) energy to interrupt the parasympathetic nerves responsible for key symptoms associated with chronic rhinitis, such as chronic nasal congestion and rhinorrhea (runny nose). The system is designed strategically to enhance patient comfort and outcomes while providing ENT specialists with an efficacious tool for delivering care.

Dr. Peter Manes, an Associate Professor at the Yale School of Medicine, commented on the substantial impact of this policy update. He emphasized that chronic rhinitis can significantly reduce an individual's quality of life, and patient access to all medically sound treatment options is crucial. The recent update alleviates administrative obstacles, allowing otolaryngologists to offer a state-of-the-art, evidence-supported treatment option that is less encumbered by procedural limitations.

Key Changes for Healthcare Providers

1. CPT 31242 Updates: Cigna's new policy designates CPT 31242 as non-investigational, which is a critical step in ensuring coverage.
2. Precertification Adjustments: Under the updated policy, precertification is no longer necessary (it's always advisable to confirm benefits per individual plans).
3. Streamlined Access: This policy enhances accessibility to NEUROMARK for eligible patients, thus helping healthcare providers deliver timely care.

Restoring Patient Access

As chronic rhinitis management continues to advance, the NEUROMARK system stands out due to its commitment to innovation and patient care. Neurent Medical remains dedicated to expanding its evidence base and fostering collaboration with organizations like the American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) to facilitate broader adoption within the US healthcare landscape.

About Neurent Medical

Neurent Medical is on a mission to innovate treatment options for chronic inflammatory sinonasal diseases targeting hyperactive autonomic nerves that cause exacerbated inflammation. Through its NEUROMARK technology, backed by advanced smart algorithms, physicians can accurately disrupt multiple nerve branches with precision in a single procedure to significantly alleviate chronic rhinitis symptoms and improve patient well-being. Headquartered in Galway, Ireland, with a US office in Braintree, Massachusetts, Neurent Medical is at the forefront of transforming chronic rhinitis care.

For more details about the NEUROMARK system, visit Neuromark's official website.